Title
Category
Credits
Event date
Cost
Advances in Non-Steroidal Topicals: PDE-4 Inhibitors for Seborrheic Dermatitis and Beyond
  • LivDerm
  • TME
  • 0.75 AMA PRA Category 1 Credit™
  • 0.75 ANCC
  • 0.75 Participation
$0.00
Traditional treatments for seborrheic dermatitis, including oral and topical steroids, present a variety of challenges including lack of efficacy, adverse events with long-term use, limitations for adherence, and the inability to treat both hair- and non-hair-bearing areas. Recently, the first targeted therapy for treatment of seborrheic dermatitis, a PDE-4 inhibitor topical foam, was approved by the FDA.
A New Wave of Topical Therapies for Atopic Dermatitis: Comparing Treatment Approaches
  • LivDerm
  • TME
  • 1.00 AANP
  • 1.00 AAPA Category I CME
  • 1.00 AMA PRA Category 1 Credit™
  • 1.00 ANCC
  • 1.00 Participation
$0.00
Topical therapies are considered the mainstay treatment for atopic dermatitis (AD). However, traditional topicals such as corticosteroids and calcineurin inhibitors are associated with limitations for use and safety concerns. In addition, treatment guidelines for AD provide few to no recommendations for selecting therapies and, as a result, treatment selection for each patient can be complex and subjective. New targeted topical therapies are becoming increasingly available, and clinicians must be familiar with the latest clinical data and how to utilize them in clinical practice.
Addressing Unmet Needs and Disease Burden in Chronic Spontaneous Urticaria: A Clinical Escape Room Challenge
  • LivDerm
  • TME
  • 0.50 AMA PRA Category 1 Credit™
  • 0.50 ANCC
  • 0.50 Participation
$0.00
Chronic spontaneous urticaria (CSU) has unpredictable symptoms without an obvious external cause; however, the symptoms of CSU, such as hives, itching and swelling, mimic an allergic reaction, and there is often significant time spent finding an external trigger. Despite current treatment options for CSU, treatment resistance and poor symptom control remain significant challenges; only 40% of patients achieve complete symptom control with standard therapy.